Education
About Us
Working with TipRanks
Follow Us
Rani Therapeutics Holdings (RANI)
NASDAQ:RANI
Total Valuation
Rani Therapeutics Holdings has a market cap or net worth of $40.02M. The enterprise value is $26.10M.
Market Cap$40.02M
Enterprise Value$26.10M
Share Statistics
Rani Therapeutics Holdings has 47,898,228 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding47,898,228
Owned by Insiders20.34%
Owned by Institutions8.85%
Financial Efficiency
Rani Therapeutics Holdings’s return on equity (ROE) is -15.07 and return on invested capital (ROIC) is -302.68%.
Return on Equity (ROE)-15.07
Return on Assets (ROA)-0.82
Return on Invested Capital (ROIC)-302.68%
Return on Capital Employed (ROCE)-3.18
Revenue Per Employee9.79K
Profits Per Employee-538.90K
Employee Count105
Asset Turnover0.03
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Rani Therapeutics Holdings is ―. Rani Therapeutics Holdings’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value19.58
Price to FCF―
Price to Operating Cash Flow-0.62
PEG Ratio―
Income Statement
In the last 12 months, Rani Therapeutics Holdings had revenue of 1.03M and earned -30.02M in profits. Earnings per share was -1.05.
Revenue1.03M
Gross Profit1.03M
Operating Income-53.31M
Pretax Income-30.02M
Net Income-30.02M
EBITDA-50.52M
Earnings Per Share (EPS)-1.05
Cash Flow
In the last 12 months, operating cash flow was -31.01M and capital expenditures -244.00K, giving a free cash flow of -31.25M billion.
Operating Cash Flow-31.01M
Free Cash Flow-31.25M
Free Cash Flow per Share-0.65
Dividends & Yields
Rani Therapeutics Holdings pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.67
52-Week Price Change-79.93%
50-Day Moving Average0.53
200-Day Moving Average1.24
Relative Strength Index (RSI)54.81
Average Volume (3m)3.35M
Important Dates
Rani Therapeutics Holdings upcoming earnings date is Nov 12, 2025, After Close (Confirmed).
Last Earnings DateAug 7, 2025
Next Earnings DateNov 12, 2025
Ex-Dividend Date―
Financial Position
Rani Therapeutics Holdings as a current ratio of 1.50, with Debt / Equity ratio of -347.77%
Current Ratio1.50
Quick Ratio1.50
Debt to Market Cap0.63
Net Debt to EBITDA-0.51
Interest Coverage Ratio-10.59
Taxes
In the past 12 months, Rani Therapeutics Holdings has paid 26.57M in taxes.
Income Tax26.57M
Effective Tax Rate-0.89
Enterprise Valuation
Rani Therapeutics Holdings EV to EBITDA ratio is -1.29, with an EV/FCF ratio of -1.82.
EV to Sales63.19
EV to EBITDA-1.29
EV to Free Cash Flow-1.82
EV to Operating Cash Flow-1.83
Balance Sheet
Rani Therapeutics Holdings has $10.22M in cash and marketable securities with $19.39M in debt, giving a net cash position of $9.17M billion.
Cash & Marketable Securities$10.22M
Total Debt$19.39M
Net Cash$9.17M
Net Cash Per Share$0.19
Tangible Book Value Per Share$0.12
Margins
Gross margin is 58.42%, with operating margin of -5186.19%, and net profit margin of -2920.04%.
Gross Margin58.42%
Operating Margin-5186.19%
Pretax Margin-2920.04%
Net Profit Margin-2920.04%
EBITDA Margin-4914.69%
EBIT Margin-5014.69%
Analyst Forecast
The average price target for Rani Therapeutics Holdings is $7.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$7.00
Price Target Upside1150.00% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast22.94%